-
公开(公告)号：US20190295706A1
公开(公告)日：2019-09-26
申请号：US16434977
申请日：2019-06-07
发明人： Michael Har-Noy
摘要： The present disclosure relates to an apparatus for dispensing biologic drug compositions. The apparatus includes an automated device that can store a biologic drug under the desired conditions. When authorized, the automated device can process the stored biologic drug by performing the desired processing steps to prepare the biologic drug for administration to a patient. The automated device may include a computing system to transmit patient information to a remote location and receive authorization from a remote location.
-
公开(公告)号：US10272143B2
公开(公告)日：2019-04-30
申请号：US14592701
申请日：2015-01-08
发明人： Michael Har-Noy
摘要： Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
-
公开(公告)号：US20190105350A1
公开(公告)日：2019-04-11
申请号：US16215116
申请日：2018-12-10
发明人： Michael Har-Noy
IPC分类号： A61K35/28 , A61K39/39 , C12N5/0783 , A61K39/00
摘要： The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.
-
公开(公告)号：US20160361404A1
公开(公告)日：2016-12-15
申请号：US15245845
申请日：2016-08-24
发明人： Michael Har-Noy
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/1774 , A61K38/217 , A61K39/39 , A61K2035/122 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , A61K2039/57 , C12N5/0637 , C12N2502/1114 , A61K2300/00
摘要： The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effectore T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.
摘要翻译： 本发明涉及抑制患者中疾病或疾病抗原的免疫耐受性的方法。 该方法还促进了有效T淋巴细胞的活性。 本发明包括施用在患者中促进Th1环境的治疗组合物，同时降低Treg细胞的免疫抑制活性，其可以导致患者的疾病抗原抗性和疾病抗原的免疫吸收。 治疗组合物包括同种异体emTh-1细胞。 治疗组合物还可以包括疾病抗原，例如疾病抗原的富含分子伴侣的细胞裂解物。
-
5.发明申请Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome 审中-公开人体免疫缺陷病毒/后天免疫缺陷综合征的治疗公开(公告)号：US20150190488A1
公开(公告)日：2015-07-09
申请号：US14592701
申请日：2015-01-08
发明人： Michael Har-Noy
CPC分类号： A61K39/0005 , A61K35/17 , A61K45/06
摘要： Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
摘要翻译： 公开了治疗患有人体免疫缺陷病毒的患者的方法。 该方法包括提供皮肤和静脉内剂量的aTh1组合物，其可增加耐药HIV患者的CD4 +细胞。 该描述包括病毒载量减少的方法和病毒清除方法。 该方案导致病毒载量的尖峰，然后导致病毒的基线或较低水平的返回，并且可导致潜伏病毒储库的减少和/或消除。 还包括配置为根据方案提供皮内剂量和静脉内剂量的试剂盒。
-
公开(公告)号：US11037087B2
公开(公告)日：2021-06-15
申请号：US16434977
申请日：2019-06-07
发明人： Michael Har-Noy
摘要： The present disclosure relates to an apparatus for dispensing biologic drug compositions. The apparatus includes an automated device that can store a biologic drug under the desired conditions. When authorized, the automated device can process the stored biologic drug by performing the desired processing steps to prepare the biologic drug for administration to a patient. The automated device may include a computing system to transmit patient information to a remote location and receive authorization from a remote location.
-
公开(公告)号：US10729754B2
公开(公告)日：2020-08-04
申请号：US15922600
申请日：2018-03-15
发明人： Michael Har-Noy
摘要： Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
-
公开(公告)号：US20170290857A1
公开(公告)日：2017-10-12
申请号：US15630581
申请日：2017-06-22
发明人： Michael Har-Noy
IPC分类号： A61K35/17 , C12N5/0783 , A61K39/00
CPC分类号： A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5152 , A61K2039/5158 , A61K2039/545 , A61K2039/57 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515
摘要： The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
-
公开(公告)号：US20150024006A1
公开(公告)日：2015-01-22
申请号：US14500395
申请日：2014-09-29
发明人： Michael Har-Noy
IPC分类号： A61K39/00
CPC分类号： A61K39/0002 , A61K35/17 , A61K39/0005 , A61K2039/5158 , A61K2039/55588 , A61K2039/57
摘要： A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.
摘要翻译： 一种刺激免疫受损患者免疫系统以治疗机会性感染的方法。 该方法涉及有意错配的同种异体细胞的输注。 为了防止移植物抗宿主病并发症，可以在输注之前照射同种异体细胞。
-
公开(公告)号：US20140154278A1
公开(公告)日：2014-06-05
申请号：US14173494
申请日：2014-02-05
发明人： Michael Har-Noy
IPC分类号： A61K39/00
CPC分类号： A61K39/0005 , A61K35/17 , A61K2039/5154 , A61K2039/57 , C12N5/0636 , C12N2501/51 , C12N2501/515 , C12N2531/00 , C12N2533/40
摘要： A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.
摘要翻译： 一种操作同种异体细胞用于同种异体细胞治疗的方法，其提供高活性同种异体T细胞的组合物，其被输注到免疫活性癌症患者中以引发新的抗肿瘤免疫机制，或“镜效应”。 与当前的同种异体细胞治疗方案相比，其中移植物中的T细胞介导有益的移植物抗肿瘤（GVT）和有害的移植物抗宿主（GVH）效应，本发明的同种异体细胞刺激宿主T细胞介导 这些效果的“镜子”。 GVT效应的镜子是宿主与肿瘤（HVT）的作用。 GVH效应的“镜子”是宿主与移植物（HVG）的作用。抗肿瘤HVT效应与无毒的HVG排斥反应有关。 本发明的高度激活的同种异体细胞可以用于在患者的完全HLA不匹配的设置中刺激宿主免疫。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.02 秒)
